Ziga Rotar

Background: To compare the performances of magnetic resonance imaging (MRI) and radiography in detecting changes in structural lesions of the sacroiliac joints (SIJs) in routine care patients with axial spondyloarthritis (axSpA). Methods: SIJ MRIs and radiographs of routine care patients with axSpA in four European countries were collected as part of the EuroSpA Imaging Project. Patients were included if both MRIs and radiographs (≤ 6 months apart) were available at two time points (≥ 1 year apart). Images were evaluated centrally and independently by two trained readers (blinded to chronology and other imaging), applying the Spondyloarthritis Research Consortium of Canada SIJ scores (MRI) and the modified New York criteria (mNY, radiography). Intermodality agreement was assessed cross-sectionally and for change. Results: One-hundred-and-five patients (65 male, mean (SD) age 38.1 (10.9) years, symptom duration 9.1 (9.7) years), with a follow-up interval of 2.6 (1.4) years) were included. Baseline agreement between radiography and MRI was slight-to-fair for erosion detection (kappa = 0.12 to 0.42), poor to slight for sclerosis (− 0.04 to 0.07), and substantial to almost perfect for ankylosis (0.66–0.86). Agreement for change over time was poor-to-slight (− 0.04 to 0.20). While lesions remained largely stable on radiography (≤ 6 patients showing change in scores, per lesion type), MRI detected change in at least one lesion in ≥ 50% of patients (positive/negative change in scores (“progression”/”regression”): sclerosis 27/30, erosion 51/38, ankylosis 14/5). A composite MRI score of damage correlated well with mNY grades (Spearman rho = 0.65–0.69). Conclusions: Compared to radiography, MRI detected more SIJ structural lesion changes over time, reflecting its ability to capture dynamic changes not readily visible on radiography.

Objective: Identifying patient characteristics that predict treatment response in psoriatic arthritis (PsA) may help optimize treat-to-target strategies. We aimed to explore overall and sex-specific predictors of secukinumab (SEC) effectiveness in European patients with PsA treated in routine care. Methods: We analyzed data from 14 registries in the European Spondyloarthritis (EuroSpA) Research Collaboration. Patients aged ≥ 18 years at diagnosis, initiating SEC treatment from January 2015 to January 2021, were included. Multiple imputation was used for missing covariates at treatment start (baseline) and Disease Activity Index for Psoriatic Arthritis based on 28 joints (DAPSA28) at 6 months. Overall and sex-stratified analyses were performed by logistic and Cox regressions to identify baseline predictors of the following treatment outcomes: (1) DAPSA28 low disease activity (LDA; DAPSA28 ≤ 14) at 6 months, (2) DAPSA28 moderate response at 6 months, and (3) SEC discontinuation within 12 months. Results: In total, 2790 patients (43% male) were included. Median age was 43 years (IQR 34-52), and SEC was the first-line biologic/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) in 665 patients (24%). Positive predictors for both DAPSA28 LDA and DAPSA28 moderate response were male sex, fewer previous b/tsDMARDs, C-reactive protein (CRP) > 10 mg/L, and lower Health Assessment Questionnaire (HAQ) score. Absence of psoriasis, higher patient fatigue, and tender joint counts predicted SEC discontinuation within 12 months. For some outcomes, sex-specific predictors were fewer previous b/tsDMARDs and CRP > 10 mg/L among male patients and lower patient fatigue score among female patients. Conclusion: We identified overall and sex-specific predictors of SEC effectiveness in European patients with PsA. Our findings may support personalized treatment decisions.

Introduction: To analyse the long-term dynamics of the burden of sickness absenteeism (SA) at the societal and patient levels in employed patients with selected inflammatory rheumatic diseases (IRDs). Methods: The burden of SA was analysed over 2 decades prior to the COVID-19 pandemic, with a focus on the subperiod following the introduction of the rheumatology clinical registry biorx.si. Population data for full-time employees on sick leave due to rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) were obtained from the national administrative database. The societal burden of SA was defined as the total annual number of calendar days on sick leave. The patient-level burden of SA was defined as the average annual number of days on sick leave per patient which was further disaggregated into the average annual number of sick leave episodes per patient and the average annual number of days per sick leave episode. The costs of SA were estimated using the human capital approach. An exponential trend method was used for analysis, and time series were tested for structural breaks. Results: The societal burden of SA during the subperiod following the registry introduction decreased, on average, by 3.3% annually among RA patients. The average annual increase in the societal burden of SA was marginal for PsA patients (0.4%) and substantial for AS patients (8.7%). The societal and patient-level burdens of SA varied by sex and job sector. The patient-level burden of SA, however, decreased on average by 2.5% annually for RA patients and increased marginally for both PsA and AS patients. The key pattern suggesting potential improvements in the patient-level burden of SA for the analysed IRDs was an increase in the number of sick leave episodes per patient, offset by shorter episode duration. Conclusions: A study of the societal burden of SA, including its components, and the patient-level burden of SA can support the development of more effective strategies for managing SA and facilitating a faster return to work.

Objectives: To investigate associations between cardiometabolic comorbidities and clinical characteristics, prescription patterns and retention of first biologic/targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) in patients with psoriatic arthritis (PsA). Methods: Patients with PsA initiating a first b/tsDMARD treatment in 2015 or later were identified in eight European rheumatology registries. Patients with information on five cardiometabolic comorbidities (obesity, dyslipidaemia, diabetes, hypertension, ischaemic heart disease) at treatment start (baseline) were included. All analyses were conducted according to patients’ comorbidity burden (count: 0/1/≥2) and status (presence/absence of each comorbidity). Patient characteristics and prescription patterns were described. Twelve-month treatment retention rates were estimated and compared using Kaplan-Meier plots, log-rank tests and multivariable Cox regression analyses. Results: Among 5299 patients, 36% had at least one cardiometabolic comorbidity. Patients with comorbidity were older, had higher disease activity and more disability. Regardless of comorbidity, most patients were prescribed a tumour necrosis factor inhibitor (76%). The use of interleukin-17 inhibitors increased with comorbidity burden (0/1/≥2 comorbidities: 13%/18%/19%), whereas Janus kinase inhibitor use declined (2.3%/1.6%/0.8%). Retention rates were marginally lower with higher comorbidity burden (80%/76%/78%) (log-rank, p=0.036) and obesity (absent 79% vs present 77%) (log-rank, p=0.04). The risk of treatment withdrawal was only marginally higher in patients with higher comorbidity burden (one comorbidity: HR 1.19; 95% CI 1.02 to 1.40; ≥2 comorbidities: HR 1.18; 0.98 to 1.42). Conclusion: Patients with cardiometabolic comorbidities had higher disease activity at treatment initiation of the first b/tsDMARD. Prescription patterns varied with comorbidity burden. Cardiometabolic comorbidity burden, especially obesity, was associated with marginally lower treatment retention.

Objective: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used for assessing disease activity in patients with axial spondyloarthritis (axSpA), particularly in settings where markers of inflammation are unavailable. As no consensus on BASDAI cut‐off values exists for disease activity states in axSpA, we aimed to develop and validate such cut‐offs against external criteria. Methods: Routine care patients with axSpA initiating a biologic disease‐modifying antirheumatic drug in eight European registries were included. Receiver operating characteristic analyses against external criteria were performed to determine optimal BASDAI values for separating remission, low disease activity (LDA), high disease activity (HDA), and very high disease activity (VHDA). Follow‐up data at 6 months were used to select BASDAI cut‐off values between remission and LDA and between LDA and HDA, whereas baseline data were used to select the cut‐off for VHDA. The level of agreement between disease activity states based on BASDAI and Axial Spondyloarthritis Disease Activity Score (ASDAS) cut‐off values was assessed using the proportion of discordance and weighted kappa. Results: In this cohort of 4,633 patients, the optimal BASDAI cut‐off values between remission, LDA, HDA and VHDA were estimated to be 4,600 patients. These cut‐off values can be used for assessing disease activity and monitoring patients with axSpA, particularly when laboratory markers are unavailable.

Background: Sacroiliac joint (SIJ) MRI is commonly used in diagnosing spondyloarthritis (SpA). Current Assessment of SpondyloArthritis International Society (ASAS) recommendations on reporting SIJ MRIs in patients with known or suspected axial SpA recommend always stating whether bone marrow oedema (BME), erosions and fat lesions are present/absent and whether the MRI is compatible with axial SpA. Purpose: To investigate if routine care radiologists already report what has now been recommended and to assess the agreement between local radiologists and central SpA experts. Materials and methods: This study includes retrospective interpretation of images acquired in routine care. Patients diagnosed with SpA enrolled in a clinical registry in one of five European countries involved in the EuroSpA Collaboration, with an available SIJ MRI and an associated local MRI report, were included. MRIs were read centrally by two readers, who registered global features (eg, MRI indicative of SpA), and various inflammatory and structural lesions as present/absent. Similar information was extracted from local reports. Findings were analysed with descriptive statistics. Results: Overall, 913 patients (40 years±13, 492 men) were included. In 24%, the local MRI reports stated whether the MRI was overall indicative of SpA or not. Presence/absence of BME, erosions and fat lesions was mentioned in 88%, 48% and 29% of local reports, respectively. Inflammatory lesions were more often reported as present by local than central readers (46% vs 36%), and structural lesions less often (33% vs 50%). Conclusion: This study demonstrated a large gap between the clinical practice of reporting SIJ MRIs and recent reporting recommendations.